中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

37 records (took 0.032 seconds)

    Suppression of demyelination by interleukin-6
    11.
    发明授权
    Suppression of demyelination by interleukin-6 失效
    白介素-6抑制脱髓鞘

    公开(公告)号：US5863529A

    公开(公告)日：1999-01-26

    申请号：US530654

    申请日：1995-09-20

    Applicant: Moses Rodriguez

    Inventor： Moses Rodriguez

    IPC: A61K38/20

    CPC classification number: A61K38/204

    Abstract: A method of suppressing demyelination of the central nervous system is disclosed. The method comprises administering a therapeutically effective amount of Interleukin-6 or an analog thereof to a mammal. Methods of treating multiple sclerosis and a related article of manufacture are also disclosed.

    Abstract translation: 公开了抑制中枢神经系统脱髓鞘的方法。 该方法包括向哺乳动物施用治疗有效量的白细胞介素-6或其类似物。 还公开了治疗多发性硬化症和相关制品的方法。

    HUMAN ANTIBODIES AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF NEUROLOGICAL DISEASE
    15.
    发明申请
    HUMAN ANTIBODIES AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF NEUROLOGICAL DISEASE 审中-公开
    用于治疗神经病的人体抗体及其诊断和治疗用途

    公开(公告)号：US20130280167A1

    公开(公告)日：2013-10-24

    申请号：US13880415

    申请日：2011-10-19

    Applicant: Moses Rodriguez ,  Arthur E. Warrington ,  Larry R. Pease

    Inventor： Moses Rodriguez ,  Arthur E. Warrington ,  Larry R. Pease

    IPC: A61K39/395

    CPC classification number: A61K39/39541 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/18 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/74 ,  C07K2317/94

    Abstract: Specific binding members, particularly human antibodies, particularly recombinant antibodies, and fragments thereof, which are capable of binding to and recognizing neurons in the CNS and eliciting responses in CNS neurons are provided. The antibodies are useful for neuroprotection and in the diagnosis and treatment of conditions associated with nerve damage, injury or degeneration and neurodegenerative disease. The antibodies, variable regions or CDR domain sequences thereof, and fragments thereof of the invention may also be used in therapy in combination with chemotherapeutics, immune modulators, or neuroactive agents and/or with other antibodies or fragments thereof. Antibodies are exemplified by the antibodies IgM12 and IgM42 whose sequences are provided herein.

    Abstract translation: 提供了能够结合并识别CNS中的神经元并引起CNS神经元中的反应的特异性结合成员，特别是人抗体，特别是重组抗体及其片段。 该抗体可用于神经保护和用于诊断和治疗与神经损伤，损伤或变性和神经变性疾病相关的病症。 本发明的抗体，可变区或CDR结构域序列及其片段也可用于与化学治疗剂，免疫调节剂或神经活性剂和/或与其它抗体或其片段组合的治疗中。 抗体以本文提供其序列的抗体IgM12和IgM42为例。

    Compositions and methods including a recombinant human mab that promotes cns remyelination
    18.
    发明申请
    Compositions and methods including a recombinant human mab that promotes cns remyelination 有权
    组合物和方法，包括促进cns髓鞘再生的重组人类

    公开(公告)号：US20070086999A1

    公开(公告)日：2007-04-19

    申请号：US10557115

    申请日：2004-05-17

    Applicant: Elliot Gruskin ,  Eric Chojnicki ,  Arthur Warrington ,  Allan Bieber ,  Moses Rodriguez

    Inventor： Elliot Gruskin ,  Eric Chojnicki ,  Arthur Warrington ,  Allan Bieber ,  Moses Rodriguez

    IPC: A61K39/395 ,  A61K31/573

    CPC classification number: C07K16/28 ,  A61K31/573 ,  A61K39/39533 ,  A61K39/39541 ,  A61K2039/505 ,  A61K2039/545 ,  C07K16/18 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/75 ,  A61K2300/00

    Abstract: Antibodies, and particularly human antibodies, are disclosed that demonstrate activity in the treatment of demyelinating diseases as well as other diseases of the central nervous system that are of viral, bacterial or idiopathic origin, including dysfunction caused by spinal cord injury. Neuromodulatory agents are set forth that include and comprise a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, a hapten, active fragments thereof, agonists thereof, mimics thereof, monomers thereof and combinations thereof. Methods are described for treating demyelinating diseases, and diseases of the central nervous system of humans and domestic animals, using polyclonal IgM antibodies and human monoclonal antibodies sHIgm22(LYM 22), sHIgm46(LYM46) ebvHIgM MSI19D10, CB2bG8, AKJR4, CB2iE12, CB2iE7, MSI19E5 and MSI10E10, active fragments thereof and the like. The invention also extends to the use of human antibodies, fragments, peptide derivatives and like materials, and their use in above referenced therapeutic applications, and to pharmaceutical compositions containing them, that may be administered in desirably low doses to treat conditions involving demyelination and to promote remyelination.

    Abstract translation: 公开了抗体，特别是人类抗体，其表现出治疗脱髓鞘疾病以及中枢神经系统的病毒，细菌或特发性起源的其它疾病，包括由脊髓损伤引起的功能障碍的活性。 阐述神经调节剂，其包括并且包含选自能够结合中枢神经系统结构或细胞的抗体，肽类似物，半抗原，其活性片段，其激动剂，其模拟物，其单体 及其组合。 描述了使用多克隆IgM抗体和人单克隆抗体sHIgm22（LYM22），sHIgm46（LYM46）ebvHIgM MSI19D10，CB2bG8，AKJR4，CB2iE12，CB2iE7等治疗脱髓鞘疾病和人和家畜的中枢神经系统疾病的方法， MSI19E5和MSI10E10，其活性片段等。 本发明还延伸到人抗体，片段，肽衍生物和类似材料及其在上述治疗应用中的用途以及含有它们的药物组合物的使用，其可以以期望的低剂量施用以治疗涉及脱髓鞘的病症，以及 促进髓鞘再生。

    Method of treating autoimmune and/or viral-induced diseases that are mediated by CD8 phenotype T cells
    20.
    发明授权
    Method of treating autoimmune and/or viral-induced diseases that are mediated by CD8 phenotype T cells 失效
    治疗由CD8表型T细胞介导的自身免疫和/或病毒诱导的疾病的方法

    公开(公告)号：US5660828A

    公开(公告)日：1997-08-26

    申请号：US177806

    申请日：1994-01-06

    Applicant: Moses Rodriguez ,  Subramaniam Sriram

    Inventor： Moses Rodriguez ,  Subramaniam Sriram

    IPC: A61K38/00 ,  C07K16/28 ,  A61K39/395 ,  A61K45/05 ,  C07K1/00 ,  C07K14/00

    CPC classification number: C07K16/2815 ,  A61K38/00

    Abstract: A method to block cytolytic activity of CD8 phenotype T cells using an effective amount of a complement-fixing anti CD8 antibody is described. The anti CD8 antibody may be used to treat patients with immunopathologic disorders induced by viruses or (autoimmune diseases) such as multiple sclerosis, viral or post-viral polyneuropathy, viral or post-viral myocarditis, insulitis, encephalomyelitis, myositis, synovitus, and arthritis.

    Abstract translation: 描述了使用有效量的补体固定抗CD8抗体阻断CD8表型T细胞的溶细胞活性的方法。 抗CD8抗体可用于治疗由病毒或（自身免疫性疾病）诱导的免疫病理学障碍，例如多发性硬化，病毒性或后病毒性多发性神经病，病毒性或后病毒性心肌炎，胰岛炎，脑脊髓炎，肌炎，滑膜和关节炎 。

Patent Agency Ranking